Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KD-370,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Meiji Seika Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Hengkang entered the field of biosynthesis, improved the commercial production capacity of products in the field of biosynthesis, enriched its product pipeline by adding KD-370, a pentavalent vaccine, approved in Japan.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 01, 2023
Lead Product(s) : KD-370,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Meiji Seika Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
KEY PRODUCTS
Reset All
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
